Preferred Label : magnesium compounds;
MeSH definition : Inorganic compounds that contain magnesium as an integral part of the molecule.;
MeSH synonym : compounds, magnesium;
MeSH annotation : inorganic; GEN or unspecified; prefer specifics; DF: MAGNESIUM CPDS; general or unspecified; prefer specifics;
Is substance : O;
Origin ID : D017616;
UMLS CUI : C0206112;
ATC code(s)
- ATC code(s)
- Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- olivine [MeSH Supplementary Concept]
- See also (suggested by CISMeF)
- Semantic type(s)
- Validated automatic mappings to NTBT
Inorganic compounds that contain magnesium as an integral part of the molecule.
https://www.cochrane.org/fr/CD011358/magnesium-pour-le-traitement-de-la-drepanocytose
2019
false
false
false
France
United Kingdom
randomized controlled trials as topic
magnesium pidolate
magnesium compounds
quality of life
hospitalization
treatment outcome
review of literature
french abstract
anemia, sickle cell
magnesium
pyrrolidonecarboxylic acid
---
https://www.has-sante.fr/portail/jcms/c_2823583/fr/gastropulgite
2018
false
true
false
false
France
French
evaluation of the transparency committee
attapulgite, combinations
treatment outcome
attapulgite
drug combinations
magnesium compounds
silicon compounds
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=648949&nom=Citrate+de+magnésium
Canada
French
citrates
magnesium compounds
organometallic compounds
magnesium citrate
toxicological data sheet
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-04/mag_2_sans_sucre_-_ct-_9794.pdf
http://www.has-sante.fr/portail/jcms/c_1046817/mag-2-sans-sucre
2011
France
French
pyrrolidonecarboxylic acid
magnesium compounds
magnesium pidolate
administration, oral
pharmaceutical solutions
magnesium deficiency
adult
child
infant
magnesium pidolate
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-05/magnesiumcarence_art56_avis_has.pdf
http://www.has-sante.fr/portail/jcms/c_951087/specialites-a-base-de-magnesium-non-associe-dans-les-carences-averees
2010
France
French
magnesium
magnesium deficiency
magnesium compounds
adult
child
administration, oral
chronic disease
intestinal diseases
kidney diseases
drug information
---
http://www.has-sante.fr/portail/jcms/c_815923/magne-b6-et-uvimag-b6-magnesium-vitamine-b6
http://www.has-sante.fr/portail/jcms/c_725222/magne-b6-ct-5954
http://www.has-sante.fr/portail/jcms/c_725229/uvimag-ct-5987
2009
France
French
pyrrolidonecarboxylic acid
pyridoxine
magnesium
lactates
magnesium deficiency
glycerophosphates
drug combinations
magnesium lactate
magnesium (different salts in combination)
magnesium compounds
evaluation of the transparency committee
guidelines for drug use
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-07/ct-4967_uvimag_.pdf
http://www.has-sante.fr/portail/jcms/c_676910/uvimag
2008
France
French
evaluation of the transparency committee
dietary supplements
administration, oral
drug combinations
glycerophosphates
magnesium compounds
pyridoxine
vitamin B complex
insurance, health, reimbursement
magnesium deficiency
magnesium (different salts in combination)
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-07/ct-4802_magneb6_.pdf
http://www.has-sante.fr/portail/jcms/c_676874/magne-b6
2008
France
French
administration, oral
drug combinations
lactates
magnesium compounds
pyrrolidonecarboxylic acid
pyridoxine
magnesium lactate
magnesium (different salts in combination)
insurance, health, reimbursement
magnesium deficiency
dietary supplements
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-07/ct-5010_megamag_.pdf
http://www.has-sante.fr/portail/jcms/c_676914/megamag
2008
France
French
aspartic acid
magnesium compounds
administration, oral
magnesium aspartate
insurance, health, reimbursement
adult
child
magnesium deficiency
dietary supplements
guidelines for drug use
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct032150.pdf
http://www.has-sante.fr/portail/display.jsp?id=c_400573
2005
France
French
administration, oral
pyrrolidonecarboxylic acid
magnesium compounds
treatment outcome
magnesium deficiency
dietary supplements
magnesium pidolate
evaluation of the transparency committee
guidelines for drug use
---
